Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Adherence news

Show

From To
'Vast majority' of elevated viral load episodes in pregnant women caused by non-adherence

Non-adherence to ART — and not pretreatment drug-resistant mutations — explain the “vast majority” of elevated viral load episodes in women initiating ART during pregnancy, according to results from a study conducted in South Africa.

Published
02 April 2019
From
Healio
Long-acting injectible antiretroviral trial begins

Can a monthly injection of two antiretroviral drugs offer a better chance of suppressing the virus than current oral regimens, among individuals with adherence challenges? A trial that will enroll some 350 volunteers with documented lapses in treatment in the preceding year and a half will seek to find out, the National Institutes of Health announced today.

Published
28 February 2019
From
Science Speaks
Uganda: Financial incentives do not boost HIV viral suppression rate

Financial incentives had no effect on viral suppression among HIV-positive adults in Uganda, according to a recent study. Researchers said these findings suggest a need for better interventions to promote the achievement of viral suppression.

Published
25 January 2019
From
Healio
Indonesia turns to Global Fund to ensure ARV stock

Amid rising concerns about the availability of antiretroviral (ARV) therapy drugs following a failed drug tender, the government has given assurances that stocks are enough until the end of this year.

Published
23 January 2019
From
The Jakarta Post
What stops people with HIV adhering to long term antiretroviral therapy?

Long term adherence to antiretroviral therapy (ART) is important in both reducing morbidly and mortality in people living with HIV and reducing transmission rates. A new study published in AIDS Research and Therapy explores people’s reasons for non-adherence to ART through a cohort in Uganda. They find travel, stigma, poor adherence education, and alternative medicine to be prominent factors.

Published
22 January 2019
From
BMC Blogs Network
Substance use does not lower adherence to PrEP in MSM

Study findings showed that substance use does not affect adherence to HIV pre-exposure prophylaxis, or PrEP, among men who have sex with men or transgender women.

Published
24 November 2018
From
Healio
Linking HIV stigma, denial and poor health 

People living with HIV who stigmatise and think negatively about themselves because of their HIV status are less likely to start treatment and reach viral load suppression.

Published
08 November 2018
From
AVERT
How substance use affects adherence to PrEP among gay and bisexual men

On average, club drug users were no more likely to miss a dose of PrEP than non-club drug users. However, club drug use (at the event level) increased the odds of missing a dose on the same day by 55 percent and the next day (e.g., a "carryover effect") by 60 percent. "This suggests that although club drug users appeared to have similar aggregate levels of adherence, their missed doses were specifically timed around instances of club drug use.

Published
24 October 2018
From
Medical Xpress
How smartphones are becoming a weapon in the global fight against tuberculosis

Mobile technologies devised by researchers at the University of California, San Diego, and Johns Hopkins are allowing patients to use their phones to record daily medication intake. The encrypted videos are sent to public health workers who can watch them from their cubicles, instead of traveling long distances every day to visit patients at their homes or workplaces.

Published
21 August 2018
From
STAT
Should Gilead Be Worried About This New Monthly HIV Medication?

Yesterday, Johnson & Johnson and ViiV Healthcare announced positive results from the Atlas phase 3 study testing their two-drug HIV treatment containing an investigational drug cabotegravir and rilpivirine, a nucleoside reverse transcriptase inhibitor (NRTI) sold by Johnson & Johnson as Edurant. The important thing here isn't going from three medications to two, but that ViiV and Johnson & Johnson's cabotegravir and rilpivirine combination is injected once a month compared to a daily therapy for the three-drug combination.

Published
16 August 2018
From
Motley Fool
← First12345...15Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.